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Background: Signal transducers and activators of transcription (STATs) play a critical role in antiviral
defence. STAT3 is also important in cell protection against inflammatory damage. STAT proteins are
activated by interferons and by hepatoprotective cytokines of the interleukin 6 superfamily, including
cardiotrophin 1.
Methods: We analysed the status of STATs in hepatitis C virus (HCV) infected livers and the relationship
between expression and activation of STATs and HCV replication in Huh7 cells transfected with HCV
genomic replicon.
Results: STAT3a expression was reduced in HCV infected livers showing an inverse correlation with serum
alanine aminotransferase. In patients with HCV infection, nuclear staining for phosphorylated STAT3 was
faint in parenchymal cells (although conspicuous in infiltrating leucocytes), in contrast with strong nuclear
staining in hepatocytes from control livers. Expression and activation of STAT1 (a factor activated by both
interferon (IFN)-a and IFN-c) were increased in HCV infected livers, particularly in those with high
inflammatory activity. Conversely, phosphorylated STAT2 (a factor selectively activated by IFN-a) was
undetectable in livers with HCV infection, a finding that was associated with marked downregulation of the
two functional subunits of the IFN-a receptor. HCV replication in Huh7 cells caused STAT3a
downregulation and blocked STAT3 phosphorylation by either IFN-a or cardiotrophin 1. HCV replication
in Huh7 cells also inhibited STAT1 and STAT2 activation by IFN-a while there was no impairment of STAT1
phosphorylation by the proinflammatory cytokine IFN-c.
Conclusions: STAT3 is downregulated in HCV infected livers and in Huh7 cells bearing the full length HCV
replicon. HCV replication is associated with impaired Jak-STAT signalling by antiviral and cytoprotective
cytokines. These effects may favour viral replication while facilitating the progression of liver disease.
S
ignal transducers and activators of transcription (STATs)
are a family of proteins unique in their ability to both
transduce extracellular signals and regulate transcrip-
tion directly.1 STATs transmit extracellular signals from
growth factors and cytokines such as type I and type II
interferons (IFNs) and the interleukin (IL)-6 superfamily
(which includes IL-6, cardiotrophin-1 (CT-1), and oncostatin,
among others). The interaction of these cytokines with
specific surface receptors triggers activation of STATs through
phosphorylation at specific tyrosine residues by the receptor
associated Jak kinases. Once phosphorylated, STATs homo-
or heterodimerise and this is followed by nuclear transloca-
tion and transcriptional regulation of STAT responsible genes.
It is well documented that activation of STAT1 and STAT2
is essential for the antiviral effect of IFNs.2 3 It has also been
shown that activation of STAT3 is necessary for IFN-a to
exert its antiviral activity.4 Recent data indicate that STAT3
induces anti- hepatitis C virus (HCV) activity in liver cells.5 In
addition to its role in defence against viral infection, STAT3
exerts potent cytoprotective and anti-inflammatory effects.6–8
It has been reported that STAT3 activation by CT-1 or IL-6
provides hepatoprotection in various models of liver injury.9–13
CT-1 is a particularly hepatoprotective cytokine which, in
contrast with IL-6, is synthesised by liver parenchymal
cells.9 10 The IL-6 family of cytokines use the common
receptor subunit gp130 for signal transduction. Binding to
the receptor results in activation of gp130 associated kinases
and phosphorylation of STAT3 and STAT1.14 15 Type I IFNs
bind to a receptor composed by two subunits, IFNAR1 and
IFNAR2.16 IFNAR2 has three splicing forms, including full
length IFNA2Rc, short form IFNAR2b, and soluble form
IFNAR2a. The full length IFNAR2c is involved in both ligand
binding and signal transduction, whereas both the short form
IFNAR2b and the soluble form IFNAR2a have been impli-
cated in suppression of type I IFN signalling.17 Signal
transduction is mediated by Jak kinases, which phosphor-
ylate STAT1, STAT2, and STAT3 proteins.2 18 In the case of
type II IFN (IFN-c), binding to receptor leads to phosphor-
ylation of STAT1.19
Negative regulators of STATs include suppressor of
cytokine signalling (SOCS) family members20 SOCS1 and
SOCS3 which prevent phosphorylation of STATs by inhibiting
receptor associated Jak kinases.21 In addition, gene transcrip-
tion can be inhibited by protein inhibitor of activated STATs
(PIAS).22 23 PIAS1 and PIAS3 inhibit binding of STAT1 and
STAT3, respectively, to response elements in promoters of
target genes.
HCV causes persistent infection in 70–80% of patients,
indicating that this agent has developed efficient mechan-
isms to escape host antiviral defences. As STATs are essential
Abbreviations: CH-C, chronic hepatitis C; CT-1, cardiotrophin 1; HCV,
hepatitis C virus; IFN, interferon; IFNAR, interferon a/b receptor; IL,
interleukin; PIAS, protein inhibitor of activated STAT; RT-PCR, reverse
transcription-polymerase chain reaction; SOCS, suppressor of cytokine
signalling; STAT, signal transducer and activator of transcription
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to set in motion antiviral and cytoprotective mechanisms
within the infected cell, in the present work our aim was to
analyse expression and activation of STATs in the liver of
patients with chronic hepatitis C (CH-C) and to correlate
these changes with liver damage and level of HCV replication.
To determine whether alterations of STATs observed in CH-C
could be ascribed to the presence of replicating HCV in liver,
we investigated expression of STATs and induction of the
Jak-STAT signalling pathway by IFNs and CT-1 in hepatoma
cells transfected with a full length HCV replicon.
PATIENTS AND METHODS
Patients
Liver biopsies were obtained from 61 CH-C patients.
Diagnosis of CH-C was based on elevation of serum
transaminases for more than six months, positivity for anti-
HCV antibodies, presence of HCV-RNA by reverse transcrip-
tion-polymerase chain reaction (RT-PCR), and histological
evidence of chronic hepatitis. Alcohol consumption and other
causes of liver disease were excluded. None of the patients
had received antiviral treatment in the six months before the
study. Liver biopsies were divided into two parts. The first
part (approximately two thirds) was used for histological
examination and the second for RNA or protein extraction.
Because the amount of tissue was not enough to perform all
determinations, two different cohorts of CH-C patients were
analysed. The first cohort (n = 34) was used for RNA
extraction. In the second cohort (n = 24) we performed
extracts for total protein. Normal liver samples were obtained
from 28 patients at laparotomy. Intervention was performed
because of gastrointestinal neoplasm in 11 cases, pancreatic
tumour in nine cases, cholelithiasis in four cases, hydatidic
cyst in two cases, cholangiocarcinoma in one case, and hiatal
hernia in one case. These subjects had not received anti-
inflammatory or cytotoxic therapy previous to operation, and
in all cases histological examination of biopsy material
showed normal liver architecture. We also studied liver
biopsies from another control group (n = 24) with miscella-
neous liver disorders unrelated to HCV (nine chronic
hepatitis B, one drugs, one primary biliary cirrhosis, 10
autoinmune hepatitis, three steatohepatitis). In this mis-
cellaneous group, liver damage was similar to that of CH-C
patients. The main biochemical, virological, and histological
features of patients at the time of liver biopsy are described in
table 1. Written consent was obtained in all cases.
Generation of HCV replicon cell l ines
Huh7 cells expressing full length HCV replicon were
established as described previously.24 Briefly, pI389/Core-39/
5.1 (kind gift from Dr Bartenschlager) were linearised with
ScaI and used as templates for RNA synthesis using the T7
RNA polymerase (Promega, Madison, Wisconsin, USA).
Synthesised RNA (20 mg) was used to electroporate 107
Huh7 cells and 24 hours later 500 mg/ml of G418 were added.
Twice a week culture medium supplemented with G418 was
replaced and four weeks after transfection the colonies
resistant to G418 were collected, mixed, and used for further
analysis.
After pretreating the HCV replicon cells for six hours with
50 mmol/l of AG490 (Calbiochem, Darmstadt, Germany),
which is an inhibitor of STAT3 activation, cells were treated
for 48 hours with 50 U/ml of IFN-a in the presence of AG490
and harvested for western blot or mRNA expression analysis.
Antibodies
Anti-phospho-STAT1tyr701, anti-phospho-STAT3tyr705 antibo-
dies, and antirabbit IgG horseradish peroxidase linked
antibody were purchased from Cell Signaling Technology
(Beverly, Massachusetts, USA). Anti-STAT3, anti-phospho-
STAT1ser727, anti-STAT2, and anti-phospho-STAT2tyr689 anti-
bodies were from Upstate Biotechnology (Lake Placid, New
York, USA). Anti-STAT1 antibody was from Santa Cruz
Biotechnology (Santa Cruz, California, USA). Antiactin anti-
body was from Sigma-Aldrich (Steinheim, Germany).
RNA and protein extraction from liver tissues
Before RNA extraction, liver tissue was homogenised in 1 ml
of Ultraspec (Biotex, Houston, Texas, USA) and total RNA
was obtained following the Ultraspec protocol, which is based
on the method described by Chomczynski and Sacchi.25
Liver total protein was obtained as follows: tissue was
homogenised in 200 ml of lysis buffer containing 10 mmol/l
Tris-Cl, pH 7.4, 1 mmol/L KCl, and 0.1 mmol/l EGTA,
supplemented with 1 mg/ml aprotinin, 1 mmol/l PMSF, 10
mg/ml trypsin inhibitor, 10 mg/ml leupeptin, 1 mg/ml pepsta-
tin, 1 mM Na2VO4, and 1 mM NaF. Protein extracts were
collected by centrifugation at 100 000 g for 45 minutes and
supernatants were stored at 280 C˚.
Analysis of mRNA expression by quantitative real
time PCR
Total RNA (2 mg) was treated with DNase (Gibco-BRL,
Paisley, UK) prior to RT with M-MLV reverse transcriptase
(Gibco-BRL) in the presence of RNaseOUT (Gibco-BRL).
STATs, IFNAR, PIAS, SOCS3, HCV, and b-actin expression
were measured by quantitative real time PCR using a
LightCycler (Roche Diagnostic, Mannheim, Germany) and
LC-DNA Master SYBR Green mix. Aliquots of 2 ml from the
cDNA pool were used for each PCR, containing upstream and
downstream primers for each gene (table 2). To determine
Table 1 Clinical features of patients enrolled in the study
Characteristic HCV+ group
Normal liver
group
Miscellaneous
group
Serum biochemistry (mean (SD))
AST (IU/l) 58.1 (47.2) 15.1 (4.4) 70.8 (49.8)
ALT (IU/l) 91.1 (71.1) 19.0 (9.1) 119.2 (78.9)
GGTP (IU/l) 48.3 (51.8) 30.1 (16.3) 156.7 (265)
Albumin (g/dl) 4.16 (0.3) – 4.6 (0.43)
Viral load (IU/ml) (median (range)) 6.76106 (154–1.66108) – –
Genotype (n)
1b 34 – –
Non-1b 15 – –
Non determined 9 – –
Inflammatory activity 6.6 (2.5) – 5.7 (3.3)
Fibrosis score 1.2 (1.1) – 1.5 (1.7)
HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGTP, c-glutamyl
transpeptidase.
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specificity, final PCR products were analysed by melting
curves and electrophoresis. Results were normalised to
b-actin. The amount of each transcript was expressed by
the formula:
2ct(actin)2ct(gene)
ct being the point at which fluorescence rises appreciably
above background fluorescence.
Western blot analysis
Total liver protein (60 mg) was loaded onto sodium dodecyl
sulphate-7.5% polyacrylamide gels. After electrophoresis, it
was transferred to nitrocellulose membranes (Bio-Rad
Laboratories). Membranes were incubated in TBS-T
(50 mM Tris-HCl (pH 7.6), 200 mM NaCl, and 0.1% Tween-
20) with 5% dry milk. Proteins were detected by incubation
with specific antibody in TBS-T. After extensive washing,
horseradish peroxidase conjugated antibody was added for
one hour. Protein bands were visualised using the enhanced
chemiluminescence detection system (Perkin Elmer, Boston,
Massachusetts, USA). Membranes were autoradiographed
and bands were quantified by densitometric analysis
(Molecular Analyst/PC software; Bio-Rad).
STAT2 immunoprecipitation
Human liver protein (700 mg) was incubated with 6 mg of
anti-STAT2 antibody overnight at 4 C˚ and then added to
protein G-sepharose for two hours at 4 C˚. After sodium
dodecyl sulphate-polyacrylamide gel electrophoresis and
transfer onto nitrocellulose membrane, protein was detected
with anti-phospho-STAT2tyr689 antibody.
Phospho-Stat3 immunohistochemistry
Liver sections (4 mm) were cut from paraffin blocks and
captured on electrically charged slides. Sections were dewaxed
in xylene and taken through a series of ethanol washes. Antigen
retrieval was performed by microwave pressure cooking for five
minutes at full pressure in 10 mmol/l sodium citrate buffer
(pH 6). Endogenous peroxidase activity was blocked by
incubation in 3% hydrogen peroxide for 30 minutes. Phospho-
STAT3 antibody was incubated at a dilution of 1:25 overnight at
4˚ C and immunodetection was performed with the EnVision
system (DakoCytomation, Carpinteria, California, USA).
Incubations either omitting the specific antibody or containing
rabbit normal serum (Dako) were used as a negative control.
Sections were counterstained with methyl green.
Table 2 Primers used in this study
Gene Sense primer (59-39) Antisense primer (59-39)
STAT1 GCTATTCACAACCACTCATTCA ACAAGATACAGCCACATAGACA
STAT3a GTCCGTGGAACCATACACAA CAATGGTATTGCTGCAGGTG
STAT3b GTCCGTGGAACCATACACAA ACTGCATCAATGAATGGTGTC
SOCS3 TGCGCCTCAAGACCTTCAGC GATGCGCAGGTTCTTGGTCC
PIAS3 TGCTGGCCGGAACAAGAGTG AGGGGGCAAAGAGAGAAGGG
PIAS1 TCCCACCCAATCTTTGTGTG GCCGCATTTTACCAAGTGGA
IFNAR1 AAACAGTCTGGAAACACGCCTG CGCAGCATAAATGACAAACGG
IFNAR2c CCAAAGTCTTGAATTTTCATAAC TGCCTCAGTATCGCTATCAC
IFNAR2a CCAGGAATCAGAATTTTCATAAC TGCCTCAGTATCGCTATCAC
IFNAR2b TCACAGGTGCAGTCATAATG TGCCTCAGTATCGCTATCAC
b-actin AGCCTCGCCTTTGCCGA CTGGTGCCTGGGGCG
HCV CCTGTGAGGAACTACTGTCT CTATCAGGCAGTACCACAAG
STAT, signal transducer and activator of transcription; SOCS, suppressor of cytokine signalling; PIAS, protein
inhibitor of activated STAT; IFNAR, interferon a/b receptor; HCV, hepatitis C virus.
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Figure 1 Quantitation of signal
transducer and activator of
transcription (STAT)3 and suppressor of
cytokine signalling (SOCS)3 mRNA
levels by real time polymerase chain
reaction in the liver: relationship to
serum transaminases. (A, B) STAT3a
and STAT3b mRNA expression in
normal liver (C), in liver from patients
with chronic hepatitis C (CH-C), and in
liver from a miscellaneous group of
patients with liver diseases unrelated to
hepatitis C virus (HCV) (Other).
(C) Relationship between the level of
STAT3a mRNA expression in the liver
and serum alanine aminotransferase
(ALT) levels in patients with CH-C.
(D) SOCS3 mRNA expression in normal
liver, in liver from patients with CH-C
and in liver from a miscellaneous group
of patients with liver diseases unrelated
to HCV.
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Statistical analysis
Normality was assessed using the Shapiro-Wilk W test.
Statistical analyses were performed using parametric
(Student’s t test) and non-parametric (Kruskal-Wallis and
Mann-Whitney U) tests. Correlation was assessed by
Spearman’s or Pearson’s correlation coefficients. All p values
were two tailed and were considered significant if the
associated value was less than 0.05. Descriptive data for
continuous variables are reported as means (SD) or as
medians (interquartile range). SPSS 9.0 for Windows was
used for statistical analysis.
RESULTS
Expression of STAT3 in liver tissue
STAT3 has two splice forms, STAT3a and STAT3b, STAT3b
being a dominant negative regulator of STAT3.26 As shown in
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Figure 2 Expression of signal
transducer and activator of
transcription (STAT)3 protein and
protein inhibitor of activated STAT
(PIAS)3 mRNA in liver tissue. (A)
Representative immunoblot of STAT3
isoforms, STAT3-tyrosine
phosphorylation (tyr) and the
corresponding actin in liver tissue from
patients with chronic hepatitis C (P) and
normal liver (C). (B, C) Densitometric
analysis of total STAT3a and STAT3b
protein in liver from chronic hepatitis C
patients (CH-C), in normal liver (C), and
in liver from a miscellaneous group of
patients with liver diseases unrelated to
hepatitis C virus (Other). (D) mRNA
expression of PIAS3 in normal liver (C)
and in liver from patients with CH-C
with a high (.106 UI/ml) or low
(,106 UI/ml) viral load in serum.
Figure 3 Immunohistochemical
detection of phospho-signal transducer
and activator of transcription (STAT)3 in
normal liver (B), in the liver from an
alcoholic hepatitis patient (C), and in
the liver from a patient with chronic
hepatitis C virus infection and high viral
load (D). (A) Negative control without
primary antibody. Arrows indicate
nuclei of infiltrating mononuclear cells;
arrowheads indicate nuclei of
hepatocytes.
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fig 1A, mRNA levels of STAT3a were significantly decreased
in liver samples from CH-C patients compared with normal
livers and also compared with a miscellaneous group of
chronic liver diseases. However, STAT3b mRNA values were
similar in the three groups of patients (fig 1B). In CH-C
patients, STAT3a mRNA correlated inversely with serum
alanine aminotransferase (fig 1C).
SOCS3 is a target gene for STAT3, which can be considered
as a marker of STAT3 transcriptional activity. In CH-C, we
found a significant decrease in SOCS3 mRNA compared with
normal livers and with livers from other conditions unrelated
to HCV (fig 1D), suggesting impaired STAT3 function in
CH-C patients.
In parallel with these findings, western blot analysis
showed a decrease in STAT3a protein in the livers from
CH-C patients (n = 22) with respect to normal hepatic tissue
(n = 14) and samples from patients with miscellaneous
chronic liver diseases (n = 9) (fig 2A, B). Also, we found an
increase in STAT3b protein in CH-C (n = 22) compared with
normal liver (n = 14) and livers from patients with different
forms of chronic liver diseases (n = 9) (fig 2A, C).
Interestingly, we observed a positive correlation between
STAT3b protein and viral load (r = 0.5, p,0.05). PIAS3 is an
inhibitor of STAT3 activation.22 We detected a significant
decrease in PIAS3 mRNA only in those patients with low viral
load (fig 2D), suggesting that in these cases there are cell
mechanisms tending to prevent STAT3 inactivation.
Levels of phosphorylated STAT3 (as assessed by western
blot) showed overlap between HCV patients and controls
(data not shown). However, as in HCV infected livers STAT3
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Figure 4 Quantitation of signal
transducer and activator of
transcription (STAT)1 mRNA by real
time polymerase chain reaction in liver
tissue. (A) STAT1 mRNA values in
normal liver (C), in liver tissue from
patients with chronic hepatitis C (CH-C),
and in liver from a miscellaneous group
of patients with liver diseases unrelated
to hepatitis C virus (Other). (B) STAT1
mRNA expression in liver tissue from
CH-C patients with high (.5) or low
(,5) inflammatory activity, as
determined by the Knodell score.
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Figure 5 Signal transducer and activator of transcription (STAT)1 protein and mRNA expression of protein inhibitor of activated STAT (PIAS)1 in liver
tissue. (A) Representative immunoblot of total STAT1, STAT1-tyrosine phosphorylation (tyr), STAT1-serine phosphorylation (ser), and the corresponding
actin in liver tissue from patients with chronic hepatitis C (CH-C) (P) and normal liver (C). (B–D) Densitometric analysis of total STAT1 protein, STAT1-tyr,
and STAT1-ser in liver from CH-C patients, normal liver (C), and liver from a miscellaneous group of patients with liver diseases unrelated to hepatitis C
virus (Other). (E) Quantitation of PIAS1 mRNA level by real time polymerase chain reaction in normal liver (C) and in liver tissue from patients with CH-C.
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is expressed by different cell types, we analysed the presence
and histological distribution of activated STAT3 in liver tissue
from HCV infected patients and controls.
Immunohistochemical analysis of Tyr-STAT3 was performed
in four normal livers, in three HCV infected livers with a high
viral load, and in one patient with alcoholic hepatitis. We
found strong nuclear staining of phospho-STAT3 in hepato-
cytes both in normal livers and in alcoholic hepatitis (fig 3B,
C). In contrast, in HCV infected livers, nuclear staining was
faint in hepatocytes while it was more marked in infiltrating
mononuclear cells (fig 3D). Differences in activated STAT3
staining between parenchymal cells and cells of the
inflammatory infiltrate might explain the overlap in Tyr-
STAT3 observed in western blot studies between HCV
patients and controls. Taken together, our data indicate that
HCV infection is associated with reduced STAT3 activity in
parenchymal liver cells.
STAT1 expression in liver tissue
STAT1 mRNA abundance was significantly increased in liver
tissue from CH-C patients compared with normal livers
(fig 4A). In patients, we observed a relationship between
STAT1 mRNA levels and histological degree of liver inflam-
mation. Thus patients with high inflammatory activity (grade
6 or higher, as determined by Knodell score, n = 9) had
increased values for STAT1 mRNA compared with patients
with low inflammatory activity (grade 5 or less, n = 8)
(fig 4B). Liver STAT1 mRNA was also elevated to a similar
degree as in CH-C in a miscellaneous group of patients with
chronic hepatitis of various aetiologies (fig 4A).
Densitometric values for total and phospho-STAT1 were
significantly higher in livers from CH-C patients (n = 24) and
in livers from a miscellaneous group of chronic liver diseases
(n = 9) compared with normal liver (n = 15) (fig 5A-5D). No
relationship was found between STAT1 and viral load or
transaminases. However, STAT1-ser correlated with c-gluta-
myl-transpeptidase (r = 0.55, p,0.01) in CH-C.
PIAS1 is an inhibitor of activated STAT1 by interfering
with STAT1-DNA binding. We found a significant decrease in
PIAS1 mRNA in CH-C compared with normal livers (fig 5E),
suggesting that the effect of phospho-STAT1 on gene
transcription is not blocked by this inhibitor.
Expression of STAT2 and type I interferon receptor in
liver tissue
Total STAT2 protein was similar in CH-C and normal livers
(data not shown). Due to limitations in the sensitivity of the
analytical method for detection of phospho-STAT2 in liver, a
higher amount of tissue (obtained from explanted organs)
had to be used and an immunoprecipitation step previous to
immunoblot for STAT2-tyr was performed. We analysed three
cases of HCV induced cirrhosis and three control livers. As
shown in fig 6A, activated STAT2 was detectable in normal
liver but was completely absent in livers with HCV infection.
As STAT2 is activated specifically through type I IFN
signalling cascade, we investigated expression of IFN-a/b
receptor in liver samples. We observed that mRNA abun-
dance of IFNAR2c and IFNAR1 (the two transducing
components of receptor) were significantly lower in speci-
mens from CH-C than in normal livers while values of these
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Figure 6 Signal transducer and activator of transcription (STAT)2 protein and interferon (IFN)a/b receptor mRNA expression in liver tissue.
(A) Immunoprecipitation of total STAT2 and STAT2-tyrosine phosphorylation (tyr) in liver from patients with cirrhosis C (P) and normal liver (C).
(B) Quantitation of the full length isoform of IFNAR2 (IFNAR2c) mRNA values by real time polymerase chain reaction in normal liver (C), in liver tissue
from patients with chronic hepatitis C (CH-C), and in liver from a miscellaneous group of patients with liver diseases unrelated to hepatitis C virus
(Other). (C) IFNAR1 mRNA levels in normal liver (C), in liver tissue from patients with CH-C, and in liver from a miscellaneous group of patients with
liver diseases unrelated to hepatitis C virus.
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Figure 7 Quantification of signal
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genomic hepatitis C virus replicon cell
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transcripts were comparable with normal in a miscellaneous
group of chronic hepatitis patients (fig 6B, C). Transcriptional
expression of IFNAR2a was similar among the three groups
studied (data not shown).
Characterisation of Jak-STAT signalling pathway in
the replicon system
To analyse whether HCV replication could induce changes in
the Jak-STAT signalling cascade similar to those observed in
liver from CH-C patients, we analysed this signalling path-
way in Huh7 cells with HCV replicon.
We found that many alterations in the STATs signalling
cascade observed in CH-C livers were also present in cells
expressing the replicon. As in liver biopsies, in these cells we
detected a marked decrease in STAT3 mRNA and protein, and
also of IFNRA2c mRNA compared with control Huh7 cells
(fig 7A, B; 8A, C). Replication of HCV-RNA was also
associated with marked impairment of the IFN-a signalling
cascade with a striking defect in STAT1, STAT2, and STAT3
phosphorylation after stimulation with this cytokine (fig 8A).
Also, HCV replication markedly inhibited STAT3 phosphor-
ylation by CT-1 (fig 8C) but did not affect STAT1 activation
by either IFN-c or CT-1 (fig 8B, C).
As HCV replication in Huh7 cells caused a reduction in
both STAT3 expression and phosphorylation, we analysed
whether impairment of STAT3 activation might affect the
antiviral effect of IFN-a in cells sustaining HCV replication.
Thus we incubated the replicon cells in the presence of
AG490, an inhibitor of STAT3 phosphorylation,27 in order to
achieve more intense blockade of STAT3 activation in these
cells. As shown in fig 8D, IFN-a exhibited a reduced ability to
decrease viral load in replicon cells pretreated with AG490,
suggesting that blockade of STAT3 activation hampers the
antiviral effect of IFN-a in cells with replicating HCV.
DISCUSSION
The mechanisms by which HCV resists host antiviral defences
and induces liver injury remain poorly defined. STATs
proteins are part of a signalling pathway that is involved in
cell resistance to viral infection, cell survival, and cell
protection against inflammation induced damage.2 4 7 8 11 13 28
In this work we analysed the status of STATs in the liver of
CH-C patients and in cells supporting HCV replication. Data
in this paper show a parallel between in vivo and in vitro
findings.
STAT3 is a critical factor for cell defence against
inflammatory damage and viral infection.4 7 8 There are two
splice forms of this factor, STAT3a and STAT3b, the latter
being a dominant negative regulator of STAT3.26 In HCV
infected livers we observed an increase in STAT3b protein in
direct correlation with viral load, an observation which is in
agreement with the antiviral activity of STAT3. On the other
hand, we found that both mRNA and protein levels of
STAT3a were reduced in the liver of CH-C patients and also in
Huh7 cells with HCV replicon. These data suggest a role for
HCV in abating STAT3a expression. Interestingly, the
abundance of STAT3a mRNA correlated inversely with
alanine aminotransferase, a finding that is in keeping with
the known cytoprotective function of STAT3a. In CH-C we
also found a significant reduction in SOCS3. As SOCS3
transcription reflects STAT3 activity, our data indicate an
overall decrease in functional STAT3 in HCV infected livers.
PIAS3 is a known inhibitor of STAT3 transcriptional
activity.22 We detected a decrease in PIAS3 in those cases
with a low viral load, again suggesting an inverse relationship
between active STAT3 and HCV replication.
Our immunohistochemical observations showed lower
levels of activated STAT3 in the nuclei of hepatocytes in
livers from HCV infected patients with a high viral load
p = 0.001
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compared with controls. These data are consistent with five
additional lines of evidence that indicate derangement of
STAT3 signalling in HCV infection, namely: (1) reduced
STAT3 mRNA in HCV infected livers; (2) decreased STAT3a
protein in livers with HCV infection; (3) diminished hepatic
SOCS3 in patients with HCV infection; (4) decreased STAT3
protein in cells with HCV replicon; and (5) impaired
phospho-STAT3 on IFN-a or CT-1 stimulation in cells with
HCV replicon.
To determine whether the presence of replicating HCV
might interfere with activation of STAT3, we analysed
phosphorylation of this factor in Huh7 cells in the presence
or absence of HCV replicon after incubation of cells with
IFN-a or CT-1. We found that HCV replication blocked STAT3
phosphorylation by either IFN-a or CT-1. This effect was
rather specific as STAT1 phosphorylation by CT-1 was not
affected by the presence of HCV replicon. Therefore, HCV
appears to selectively interfere with STAT3 activation by
either antiviral (IFN-a) or hepatoprotective (CT-1) cytokines.
We found that when activation of STAT3 was blocked more
completely by incubation of replicon cells with AG490, the
antiviral effect of IFN-a was clearly reduced. Because of the
known cytoprotective effects of STAT3, blockade of STAT3
activation by HCV not only favours viral replication but may
also reduce the defence against inflammatory liver damage.
According to this view, the strategy employed by HCV to
facilitate viral replication in infected cells might simulta-
neously contribute to progression of the disease. This concept
is in agreement with the clinical observation that patients
with more advanced liver fibrosis are generally less respon-
sive to IFN therapy.29
Different reports using in vitro assays have suggested that
HCV proteins may interfere with the IFN induced Jak-STAT
signalling pathway.30–34 However, most of these studies have
been performed under conditions of forced expression of HCV
proteins without accompanying HCV replication. In contrast
with a previous report34 showing decreased STAT1 expression
in cells transfected with HCV genomic and subgenomic
constructs, we did not find a substantial decrease in STAT1
protein in replicon cells, possibly due to different experi-
mental conditions and differences in the level of HCV protein
expression in the cells. However, in our work, using the HCV
replicon system, we found that HCV replication blocks
activation of STAT1, STAT2, and STAT3 after stimulation
with IFN-a. This indicates complete interference of HCV with
the IFN-a induced Jak-STAT signalling cascade. Again, this
effect appears to be rather selective as the IFN-c signalling
pathway remains intact and IFN-c induced STAT1 phosphor-
ylation proceeds normally in cells with HCV replicon. These
observations are consistent with our findings in CH-C livers
where STAT2 phosphorylation was absent while STAT1 was
upregulated and intensely phosphorylated. Taken together
these data suggest that IFN-a signalling was abrogated in
HCV infected livers and that the intense STAT1 activation
may be due to IFN-c which is a key mediator of the
inflammatory reaction in CH-C35 and an inducer and
activator of STAT1.36 In fact, we found a relationship between
STAT1 expression and the intensity of inflammatory reaction
with higher levels of STAT1 mRNA in those with a higher
inflammatory score.
HCV interference with IFN-a signalling led us to investi-
gate expression of different subunits of the IFN-a receptor.
Previous reports using qualitative RT-PCR and immunohis-
tochemistry,37 38 have shown decreased expression of IFNAR
in liver from CH-C patients exhibiting resistance to IFN-a
therapy. Our study provides new data on IFNAR1 and
IFNAR2 splice isoforms. We observed that the two compo-
nents that are involved both in ligand binding and signal
transduction (IFNAR1 and IFNAR2c) are selectively
decreased in HCV infected livers while the soluble form
(IFNAR2a) was in the normal range. In parallel with these
results we found that replication of HCV in Huh7 cells also
causes downregulation of IFNR2c.
In summary, HCV reduces STAT3 expression in liver and
blocks STAT3 activation by either IFN-a or CT-1. In addition,
HCV inhibits IFN-a induced STAT1 and STAT2 activation but
does not affect STAT1 phosphorylation by IFN-c or CT-1. The
inhibitory effects of HCV on STAT3 expression and on
activation of the Jak-STAT signalling cascade by antiviral
and cytoprotective cytokines may favour viral replication
while facilitating progression of liver disease.
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